Literature DB >> 11834528

Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study.

Mario J Veerkamp1, Jacqueline de Graaf, Sebastian J H Bredie, Jan C M Hendriks, Pierre N M Demacker, Anton F H Stalenhoef.   

Abstract

Familial combined hyperlipidemia (FCH) is characterized by a variable expression of hypercholesterolemia and/or hypertriglyceridemia. We evaluated the variability in lipid phenotype expression over a 5-year period and studied factors affecting the lipid phenotype expression. A total of 32 families (299 subjects) were studied in 1994 and in 1999. Subjects were classified as having FCH when total cholesterol and/or triglyceride levels exceeded the 90th percentile adjusted for age and sex. In 1994, 93 (31%) of the 299 subjects were affected, whereas 206 (69%) of the subjects were unaffected relatives. In 1999, a diagnosis of FCH was consistent in 69 (74%) of the 93 subjects. So, 26% of the FCH subjects in 1994 showed a sporadic normolipidemic pattern (ie, total cholesterol and/or triglycerides <90th percentile) in 1999. Among the 206 unaffected relatives in 1994, 178 (86%) remained unaffected in 1999, and 28 (14%) developed an FCH lipid phenotype. Multiple regression analysis showed that sex (odds ratio 2.03, 95% CI 1.09 to 3.87; P=0.03) and body mass index (odds ratio 1.14, 95% CI 1.05 to 1.24; P<0.01) significantly contributed to the variability in lipid phenotype expression. Thus, a diagnosis of FCH, based on plasma total cholesterol and/or triglyceride levels, is consistent in only 74% of the subjects over a 5-year period. Two other major characteristics of our FCH group, compared with the unaffected relatives, included elevated apolipoprotein B (apoB) levels and the presence of small dense low density lipoprotein (LDL), as reflected by a low value of the parameter K (apoB 1461 +/- 305 versus 997 +/- 249 mg/L, respectively [P < 0.001]; K value -0.22 +/- 0.19 versus -0.02 +/- 0.19, respectively [P < 0.001]). We now report that the apoB concentration and the K value show less variability in time and are more consistently associated with FCH, inasmuch as affected FCH subjects, compared with the unaffected relatives, persistently show a higher apoB level and a lower value of parameter K, reflecting small dense LDL, even when they present a sporadic normolipidemic pattern. In conclusion, our results emphasize the need for reevaluation of the diagnostic criteria for FCH. We demonstrate that apoB and small dense LDL are attractive new candidates for defining FCH. Further studies are indicated to evaluate the role of apoB and small dense LDL as diagnostic criteria for FCH.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834528     DOI: 10.1161/hq0202.104059

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  13 in total

Review 1.  Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids.

Authors:  Jacqueline de Graaf; Mario J Veerkamp; Anton F H Stalenhoef
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

Review 2.  The genetics of familial combined hyperlipidaemia.

Authors:  Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Nat Rev Endocrinol       Date:  2012-02-14       Impact factor: 43.330

3.  Impaired endothelium-dependent vascular reactivity in patients with familial combined hyperlipidaemia.

Authors:  M De Michele; A Iannuzzi; A Salvato; P Pauciullo; M Gentile; G Iannuzzo; S Panico; A Pujia; G M Bond; P Rubba
Journal:  Heart       Date:  2006-06-28       Impact factor: 5.994

4.  Drug therapy of hypercholesterolaemia in children and adolescents.

Authors:  Marjet J A M Braamskamp; Frits A Wijburg; Albert Wiegman
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

Review 5.  Hypertriglyceridaemia and risk of coronary artery disease.

Authors:  Željko Reiner
Journal:  Nat Rev Cardiol       Date:  2017-03-16       Impact factor: 32.419

6.  Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.

Authors:  Thomas M van Himbergen; Seiko Otokozawa; Nirupa R Matthan; Ernst J Schaefer; Aaron Buchsbaum; Masumi Ai; Lambertus J H van Tits; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-15       Impact factor: 8.311

7.  A nutrigenomic framework to identify time-resolving responses of hepatic genes in diet-induced obese mice.

Authors:  Hyoung-Sam Heo; Eunjung Kim; Seon-Min Jeon; Eun-Young Kwon; Su-Kyung Shin; Hyojung Paik; Cheol-Goo Hur; Myung-Sook Choi
Journal:  Mol Cells       Date:  2013-06-26       Impact factor: 5.034

8.  ApoB siRNA-induced liver steatosis is resistant to clearance by the loss of fatty acid transport protein 5 (Fatp5).

Authors:  Brandon Ason; Jose Castro-Perez; Samnang Tep; Alice Stefanni; Marija Tadin-Strapps; Thomas Roddy; Thomas Hankemeier; Brian Hubbard; Alan B Sachs; W Michael Flanagan; Nelly A Kuklin; Lyndon J Mitnaul
Journal:  Lipids       Date:  2011-08-09       Impact factor: 1.880

Review 9.  Management of hypercholesterolemia in children.

Authors:  Marjet J A M Braamskamp; Barbara A Hutten; Albert Wiegman; John J P Kastelein
Journal:  Paediatr Drugs       Date:  2014-04       Impact factor: 3.930

Review 10.  Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date.

Authors:  Antonio Gaddi; A F G Cicero; F O Odoo; A A Poli; R Paoletti
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.